This is a descriptive observational open non-comparative study of the safety and efficacy of tiotropium inhalation capsule given at 18mcg once a day for 30 days among Korean patients with COPD. At Visit 1, patients who are diagnosed as COPD will be prescribed tiotropium inhalation capsule at 18mcg once daily (at the same time). Patients' FEV1 will be assessed before start of treatment (Visit 1) and at the end of the 30 day treatment period (Visit 2). Occurrence of adverse events will also be asked from the patient at the end of the 30 day treatment period. Patients will be informed by the attending physicians to immediately report the occurrence of serious adverse events.
Study Design:
Study Type
OBSERVATIONAL
Enrollment
3,008
Boehringer Ingelheim Investigational Site 1
Busan, South Korea
Boehringer Ingelheim Investigational Site 2
Busan, South Korea
Boehringer Ingelheim Investigational Site 3
Busan, South Korea
Boehringer Ingelheim Investigational Site 4
Busan, South Korea
Boehringer Ingelheim Investigational Site 5
Chugnam, South Korea
Boehringer Ingelheim Investigational Site 6
Chugnam, South Korea
Boehringer Ingelheim Investigational Site 7
Chugnam, South Korea
Boehringer Ingelheim Investigational Site 10
Daegu, South Korea
Boehringer Ingelheim Investigational Site 11
Daegu, South Korea
Boehringer Ingelheim Investigational Site 12
Daegu, South Korea
...and 61 more locations
The primary endpoint for this postmarking study is the occurrence of adverse events, anytime during the 30 day study period, which might or might not be connected with the use of Spiriva® 18 mcg inhalation capsule
Time frame: 30 days
Secondary endpoints include change in post bronchodilator FEV1 and assessment of any change in overall severity of the disease from baseline to the end of 30 day treatment.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.